Rositsa Koleva-Kolarova
PhD
Senior Researcher
Rositsa joined HERC in May 2019 as a senior researcher. Currently she works on a Horizon2020 funded project called HEcoPerMed (Health Economics for Personalised Medicine), which aims to provide guidance on state-of-the-art health economic modelling, and on financing and payment strategies for personalised medicine, to distinguish promises from reality.
Previously she held an appointment as a research fellow in health economics in the Department of Population Health Sciences, School of Population Health & Environmental Sciences, King’s College London. She worked on economic evaluation projects on stratifying antihypertensive treatment according to individuals’ ethnicity background, pharmacogenetics and pharmacogenomics for cardiovascular diseases, and evaluating new models of care (Vanguards).
Rositsa obtained her PhD from the University of Groningen, the Netherlands, and held an appointment as an assistant professor at the Department of Public Health Sciences, Faculty of Public Health, Medical University Pleven, Bulgaria.
Recent publications
-
A Comparison of the Content and Consistency of Methodological Quality and Transferability Checklists for Reviewing Model-Based Economic Evaluations.
Lim KK. et al, (2022), Pharmacoeconomics
-
Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients.
Tsiachristas A. et al, (2022), BMC Cancer, 22
-
The net benefit of personalised medicine: A systematic literature review and regression analysis.
Vellekoop H. et al, (2022), Value in Health
-
Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options Article
Koleva-Kolarova R. et al, (2022), Applied Health Economics and Health Policy
-
WHAT IS THE NET ADDED VALUE OF PERSONALISED MEDICINE? A SYSTEMATIC LITERATURE REVIEW
Vellekoop H. et al, (2022), VALUE IN HEALTH, 25, S75 - S75